trial

L-arginine add-on Therapy in Patients With Schizophrenia

NCTId NCT02398279
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 12 (actual)
Sponsored by Hacettepe University
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2011-06
Primary completion
2012-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
L-Arginine

Sponsors

Hacettepe UniversityLead Sponsor

Investigators

1
Kazım M Yazıcı, MDPrincipal Investigator

Sites

1 total
Ankara, Turkey (Türkiye)

Facts & assertions

4 sourced
Enrollment
12
Phase
NA
Primary Completion Date
2012-12
Status
COMPLETED
relationships
The graph out of here
drug
L-Arginine
drug
lead_sponsor
Hacettepe University
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Kazım M Yazıcı, MD
person